← Search another drug
PatientPulse · by PatientPartner
Sotyktu deucravacitinib
Moderate confidence
Approximately 58 public patient conversations and reviews referenced, including review site entries, patient forum threads, branded patient stories, HCP platform summaries, and healthcare news and blog articles.
Executive intelligence
The signal that moves starts & adherence
38%Positive sentiment in discussion
2,695FDA adverse-event reports
20%Flagged serious
63%Reports name female patients
The single biggest commercial risk for Sotyktu is early dropout driven by facial acne and folliculitis in the first 30 days, before therapeutic skin clearance can build patient confidence and loyalty.
- Oral convenience is Sotyktu's strongest patient-pull driver, but visible new-onset acne and folliculitis within days of initiation are triggering early abandonment before efficacy is realized.
- Cost and payer access are the dominant structural barriers; Medicare patients face roughly $25,000 annually while commercially insured patients can access $0 copay through BMS savings programs.
- Patients who have exhausted multiple biologics report meaningful skin clearance and joint benefit on Sotyktu, but the trade-off framing ('psoriasis, acne, or hives') signals an unmet shared-decision-making gap.
- Sotyktu's PsA approval in the US (March 2026) and EU (May 2026) opens a new patient segment, but rheumatologist adoption remains cautious and early launch metrics trail comparable launches.